ulocuplumab + cytarabine

Ulocuplumab + cytarabine is an investigational **pharmaceutical combination** consisting of ulocuplumab (a fully human monoclonal IgG4 antibody targeting CXCR4) and cytarabine (an approved antimetabolite nucleoside analog chemotherapy). Ulocuplumab works by inhibiting the binding of the chemokine receptor CXCR4 to its ligand CXCL12, thereby preventing signaling pathways implicated in tumor cell survival, proliferation, migration, and resistance; it also induces apoptosis via reactive oxygen species generation and inhibits actin polymerization and cell migration, notably in hematologic malignancies such as chronic lymphocytic leukemia and multiple myeloma[5][3][1]. Cytarabine is a DNA synthesis inhibitor, incorporated into DNA during the S-phase of the cell cycle, resulting in cytotoxicity against rapidly proliferating cells, particularly leukemias; its principal mechanism is inhibition of DNA polymerase and direct DNA damage[6][2][4]. This combination is primarily investigated for the treatment of **relapsed/refractory acute myelogenous leukemia (AML)**, where CXCR4 inhibition may mobilize leukemic cells into circulation, potentially increasing their susceptibility to cytarabine-mediated cytotoxicity. Ulocuplumab is not currently approved for clinical use, and clinical development for this combination has been limited to early-phase studies.

Brand names

Vyxeos Liposomal

Other names

1-beta-D-Arabinofuranosylcytosine4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinoneAracytidineCitarabinaCytarabinumCytosine arabinosideCytosine-1-beta-D-arabinofuranosideCytosine1-beta-D-arabinofuranosideCytosine 1-beta-D-arabinofuranosidecytosine-β-D-arabinofuranoside